Display options
Cite
Mates M, Fletcher GG, Freedman OC, et al. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol. 2015;22:S114-22doi: 10.3747/co.22.2322.
Mates, M., Fletcher, G. G., Freedman, O. C., Eisen, A., Gandhi, S., Trudeau, M. E., & Dent, S. F. (2015). Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Current oncology (Toronto, Ont.), 22S114-22. https://doi.org/10.3747/co.22.2322
Mates, M, et al. "Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline." Current oncology (Toronto, Ont.) vol. 22 (2015): S114-22. doi: https://doi.org/10.3747/co.22.2322
Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, Dent SF. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol. 2015 Mar;22:S114-22. doi: 10.3747/co.22.2322. PMID: 25848335; PMCID: PMC4381787.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2015 Mar;22:S114-22. doi: 10.3747/co.22.2322.

Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Current oncology (Toronto, Ont.)

M Mates, G G Fletcher, O C Freedman, A Eisen, S Gandhi, M E Trudeau, S F Dent

Affiliations

  1. Cancer Centre of Southeastern Ontario, Kinston General Hospital; and Queen's University, Kingston, ON.
  2. Program in Evidence-Based Care, Cancer Care Ontario; and Department of Oncology, McMaster University, Hamilton, ON.
  3. Durham Regional Cancer Centre, Oshawa, ON.
  4. Sunnybrook Health Science Centre, Toronto, ON.
  5. The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON.

PMID: 25848335 PMCID: PMC4381787 DOI: 10.3747/co.22.2322

Abstract

BACKGROUND: This systematic review addresses the question "What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer?"

METHODS: The medline and embase databases were searched for the period January 2008 to May 2014. The Standards and Guidelines Evidence directory of cancer guidelines and the Web sites of major guideline organizations were also searched.

RESULTS: Sixty publications relevant to the targeted therapy portion of the systematic review were identified. In four major trials (hera, National Surgical Adjuvant Breast and Bowel Project B-31, North Central Cancer Treatment Group N9831, and Breast Cancer International Research Group 006), adjuvant trastuzumab for 1 year was superior in disease-free survival (dfs) and overall survival (os) to no trastuzumab; trastuzumab showed no benefit in one trial (pacs 04). A shorter duration of trastuzumab (less than 1 year compared with 1 year) was evaluated, with mixed results for dfs: one trial showed superiority (finher), one trial could not demonstrate noninferiority (phare), another trial showed equivalent results (E 2198), and one trial is still ongoing (persephone). Longer trastuzumab duration (hera: 2 years vs. 1 year) showed no improvement in dfs or os and a higher rate of cardiac events. Newer her2-targeted agents (lapatinib, pertuzumab, T-DM1, neratinib) have been or are still being evaluated in both adjuvant and neoadjuvant trials, either by direct comparison with trastuzumab alone or combined with trastuzumab. In the neoadjuvant setting (neoaltto, GeparQuinto, Neosphere), trastuzumab alone or in combination with another anti-her2 agent (lapatinib, pertuzumab) was compared with either lapatinib or pertuzumab alone and showed superior or equivalent rates of pathologic complete response. In the adjuvant setting, lapatinib alone or in combination with trastuzumab, compared with trastuzumab alone (altto) or with placebo (teach), was not superior in dfs. The results of the completed aphinity trial, evaluating the role of dual her2 blockade with trastuzumab and pertuzumab, are highly anticipated. Ongoing trials are evaluating trastuzumab as a single agent without adjuvant chemotherapy (respect) and in patients with low her2 expression (National Surgical Adjuvant Breast and Bowel Project B-47).

CONCLUSIONS: Taking into consideration disease characteristics and patient preference, 1 year of trastuzumab should be offered to all patients with her2-positive breast cancer who are receiving adjuvant chemotherapy. Cardiac function should be regularly assessed in this patient population.

Keywords: Early breast cancer; her2; lapatinib; pertuzumab; targeted therapy; trastuzumab

References

  1. Lancet. 2007 Jan 6;369(9555):29-36 - PubMed
  2. J Clin Oncol. 2011 Dec 1;29(34):4491-7 - PubMed
  3. Lancet Oncol. 2013 Jul;14(8):741-8 - PubMed
  4. Lancet Oncol. 2012 Feb;13(2):135-44 - PubMed
  5. J Clin Oncol. 2012 Nov 1;30(31):3792-9 - PubMed
  6. Cancer Treat Rev. 2008 Oct;34(6):539-57 - PubMed
  7. J Clin Oncol. 2013 Dec 20;31(36):4504-11 - PubMed
  8. J Clin Oncol. 2010 Oct 1;28(28):4307-15 - PubMed
  9. Cancer Treat Rev. 2011 Jun;37(4):312-20 - PubMed
  10. Cancer. 2010 Jun 15;116(12):2856-67 - PubMed
  11. Trials. 2013 Aug 19;14:261 - PubMed
  12. N Engl J Med. 2011 Oct 6;365(14):1273-83 - PubMed
  13. Breast. 2011 Dec;20(6):485-90 - PubMed
  14. Clin Cancer Res. 2007 Jan 1;13(1):228-33 - PubMed
  15. J Clin Oncol. 2014 Jul 10;32(20):2159-65 - PubMed
  16. Lancet Oncol. 2012 Jan;13(1):25-32 - PubMed
  17. Ann Oncol. 2011 Sep;22(9):2007-13 - PubMed
  18. N Engl J Med. 2005 Oct 20;353(16):1673-84 - PubMed
  19. BMC Med Res Methodol. 2007 Feb 15;7:10 - PubMed
  20. Oncologist. 2013;18(7):812-8 - PubMed
  21. Lancet Oncol. 2013 Jan;14(1):88-96 - PubMed
  22. J Clin Oncol. 2011 Sep 1;29(25):3366-73 - PubMed
  23. Jpn J Clin Oncol. 2011 May;41(5):709-12 - PubMed
  24. J Clin Oncol. 2011 Feb 20;29(6):651-9 - PubMed
  25. Ann Oncol. 2011 Feb;22(2):301-6 - PubMed
  26. Lancet Oncol. 2011 Mar;12(3):236-44 - PubMed
  27. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243 - PubMed
  28. Lancet. 2013 Sep 21;382(9897):1021-8 - PubMed
  29. Lancet Oncol. 2013 Dec;14(13):1317-25 - PubMed
  30. N Engl J Med. 2005 Oct 27;353(17 ):1784-92 - PubMed
  31. PLoS One. 2011;6(6):e21030 - PubMed
  32. Lancet. 2012 Feb 18;379(9816):633-40 - PubMed
  33. J Natl Cancer Inst. 2012 Jan 18;104(2):159-62 - PubMed
  34. J Clin Oncol. 2009 Dec 20;27(36):6129-34 - PubMed
  35. Cancer Treat Rev. 2013 Oct;39(6):622-31 - PubMed
  36. Ann Oncol. 2010 Nov;21(11):2153-60 - PubMed
  37. Med Oncol. 2011 Jun;28(2):401-8 - PubMed
  38. Lancet Oncol. 2013 Mar;14(3):244-8 - PubMed
  39. J Clin Oncol. 2009 Dec 1;27(34):5685-92 - PubMed
  40. Anticancer Drugs. 2011 Feb;22(2):128-35 - PubMed
  41. Clin Oncol (R Coll Radiol). 2009 Apr;21(3):159-60 - PubMed
  42. J Clin Oncol. 2008 Mar 10;26(8):1231-8 - PubMed
  43. J Clin Oncol. 2002 Sep 1;20(17):3628-36 - PubMed
  44. Ann Oncol. 2008 Jun;19(6):1090-6 - PubMed

Publication Types